LY3437943, GGG tri-agonist · Evidence-based safety and harm-reduction overview.
| Also known as | LY3437943, GGG tri-agonist |
| Category | GLP-1 |
| trial_status | Investigational; not FDA-approved as of 2025 |
| mechanism_class | Triple GIP/GLP-1/glucagon receptor agonist |
| route | Subcutaneous injection |
| dosing_frequency | Once weekly (in trials studied) |
| US legal status | Retatrutide is INVESTIGATIONAL and is not FDA-approved for any use. It is only legitimately available within authorized clinical trials. Gray-market 'research' vials sold online are not the trial drug, are unverified, and are illegal to sell for human use. |
Retatrutide is an investigational once-weekly injectable peptide designed as a triple receptor agonist, simultaneously acting on the GIP (glucose-dependent insulinotropic peptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. It is being developed and studied primarily for obesity and metabolic disorders.
Retatrutide binds and activates three distinct G-protein-coupled receptors: GIP-R (enhancing insulin secretion in response to nutrients), GLP-1R (slowing gastric emptying and enhancing satiety signaling), and the glucagon receptor (increasing hepatic glucose output and energy expenditure). The combined effect is proposed to produce synergistic weight loss and metabolic improvement beyond single-agonist drugs.
Retatrutide (LY3437943) was developed by Eli Lilly as a next-generation obesity therapeutic combining GIP, GLP-1, and glucagon signaling. Phase 2 trials began in 2021 and generated significant media attention due to reported weight-loss results, leading to increased gray-market interest and attempted supply despite its investigational status.
Research from phase 2 clinical trials suggests retatrutide can produce substantial weight loss in treated participants, with reductions drawing significant attention in obesity research, though the highest-dose cohorts and longer-term follow-up data were not completed prior to trial pauses. Studies report incretin and glucagon-class metabolic effects on appetite suppression, energy expenditure, and glucose control, but long-term outcome and safety data remain incomplete, regulatory approval has not been achieved, and results from the actual trial drug do not validate or transfer to unregulated gray-market copies.
In clinical trials, retatrutide was studied at escalating once-weekly subcutaneous doses; however, no definitive approved or optimal human dose has been established, and gray-market dosing protocols are entirely speculative and unvalidated.
This is general research/context information, not medical advice or a recommended protocol.
Combining retatrutide with other GLP-1 agents, incretin drugs, or other metabolic peptides outside clinical trials creates redundant, unpredictable, and potentially dangerous multi-agonist effects on pancreatic and hepatic function.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsNo. Retatrutide is investigational and not FDA-approved, so it is only legitimately available within clinical trials. Vials sold online are unverified gray-market products that are not the trial drug and are illegal to sell for human use.
No. Gray-market research vials are definitely not the actual trial drug. Their identity, dose, purity, and sterility are completely unverified, which creates severe risks of mislabeling, contamination, and harm.
In mid-stage trials, some participants achieved significant weight loss, but the full trial data are not public, and long-term outcome data remain incomplete. Results from actual trial drug cannot be assumed to apply to unverified gray-market copies.
Retatrutide is still in clinical development. The FDA requires demonstration of long-term safety and efficacy before approval, and such trials can take years. Gray-market availability does not indicate proximity to approval.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.